Loading...
Please wait, while we are loading the content...
Similar Documents
Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Lepère, Céline Fléjou, Jean-François Emile, J. Des, Guetz Gaëtan Cuilliere-dartigues, P. Faron, Michael Lécaille, Cédric Validire, Pierre Louvet, Christophe Rougier, Philippe Gramont, Aimery De Bonnetain, Franck Praz, Françoise Taïeb, Julien |
| Copyright Year | 2011 |
| Abstract | PURPOSE Adding oxaliplatin to adjuvant 5-fluorouracil (5-FU) chemotherapy improves 3-year disease-free survival (DFS) after resection of stage III colon cancer. Several studies suggest that patients with tumors exhibiting defective mismatch repair (MMR) do not benefit from adjuvant 5-FU chemotherapy, but there are few data on 5-FU-oxaliplatin (FOLFOX) adjuvant chemotherapy in this setting. The aim of this study was to evaluate the prognostic value of MMR status for DFS in patients with stage III colon cancer receiving adjuvant FOLFOX chemotherapy. EXPERIMENTAL DESIGN MMR status was determined by microsatellite instability testing or immunohistochemistry in 303 unselected patients with stage III colon cancer receiving adjuvant FOLFOX chemotherapy in 9 centers. Cox proportional hazards models were used to examine the association between MMR status and 3-year DFS. RESULTS The 3-year DFS rate was significantly higher in the 34 patients (11.2% of the study population) with defective MMR tumors (90.5%) than in patients with proficient MMR tumors (73.8%; log-rank test; HR = 2.16; 95% CI, 1.09-4.27; P = 0.027). In multivariate analysis, MMR status remained an independent significant prognostic factor for DFS (HR = 4.48; 95% CI, 1.34-14.99; P = 0.015). CONCLUSION MMR status is an independent prognostic biomarker for DFS in patients with stage III colon cancer receiving adjuvant FOLFOX chemotherapy. |
| Starting Page | 905 |
| Ending Page | 913 |
| Page Count | 9 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://clincancerres.aacrjournals.org/content/clincanres/17/23/7470.full.pdf |
| Alternate Webpage(s) | http://clincancerres.aacrjournals.org/content/clincanres/early/2011/10/13/1078-0432.CCR-11-1048.full.pdf |
| PubMed reference number | 21998335v1 |
| Alternate Webpage(s) | https://doi.org/10.1158/1078-0432.CCR-11-1048 |
| DOI | 10.1158/1078-0432.ccr-11-1048 |
| Journal | Clinical cancer research : an official journal of the American Association for Cancer Research |
| Volume Number | 17 |
| Issue Number | 23 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Biological Markers Chemotherapy, Adjuvant Colon Carcinoma Excision Exhibits as Topic FOLFOX Regimen Fluorouracil Measles-Mumps-Rubella Vaccine Mismatch Repair Neoplasms Patients Pharmaceutical Adjuvants Prognostic Factors Stage III Colon Cancer Stage level 3 microsatellite instability diagnostic test oxaliplatin |
| Content Type | Text |
| Resource Type | Article |
